RxDoctor Payments Data

Sean Powers, PA

Medical · Santa Maria, CANPI 1770357972

Payments from drug & device makers

$1,749in general payments, 2019–2025

Across 35 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$474
  • SK Life Science, Inc.$125
  • Tersera Therapeutics LLC$70

What the payments were for

  • Travel & lodging$84949%
  • Food & beverage$90051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic14$1,080
AbbVie19$474
SK Life Science, Inc.1$125
Tersera Therapeutics LLC1$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,749 in reported general payments places this provider in the 70th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$124,720
Medicare patients
634
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate13$24,333
Nurtec OdtRimegepant Sulfate14$17,142
UbrelvyUbrogepant11$13,907
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen336$10,474
Gabapentin483$8,328
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen112$3,232
Baclofen186$3,055
Diclofenac Sodium45$2,932
Pregabalin112$1,989
Memantine Hcl91$1,689
Carbamazepine ErCarbamazepine14$1,602
Oxycodone Hcl73$1,555
Cyclobenzaprine Hcl66$1,018
Levetiracetam41$968
Donepezil Hcl82$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$125$24,33313 claims
AbbVieUbrelvy$474$13,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 medical providers in California.

Other medical in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →